Neuro-Oncology

Top Story

FDA grants breakthrough therapy designation to Toca 511 and Toca FC for high-grade glioma

February 24, 2017

The FDA granted breakthrough therapy designation to Toca 511 and Toca FC for the treatment of recurrent high grade glioma, according to the drugs’ manufacturer.

Toca 511 (Tocagen), an investigational injectable retroviral replicating vector, and Toca FC (Tocagen) — an investigational, orally administered, extended-release version of 5-fluorocytosine — are combined to directly kill cancer cells and immune-suppressive myeloid cells, according to a Tocagen-issued press release. This leads to activation of the immune system against cancer.

Improvements needed to better integrate PCPs into cancer survivorship care

February 24, 2017
Several cancer survivorship care models are available to help integrate primary care providers into the long-term follow-up care of cancer survivors. However, limited…

Many patients lack knowledge about advances in cancer diagnostics, treatment

February 22, 2017
A majority of patients with cancer and their caregivers lack sufficient knowledge about advances in diagnostic and treatment options, according to results of a survey…
In the Journals Plus

Many nonelderly cancer survivors alter prescription drug use to save money

February 21, 2017
Nearly one-third of nonelderly Americans recently diagnosed with cancer change their prescription drug use for financial reasons, according to an analysis published in…
FDA News

FDA grants breakthrough therapy designation to Toca 511 and Toca FC for high-grade glioma

February 24, 2017
The FDA granted breakthrough therapy designation to Toca 511 and Toca FC for the treatment of recurrent high grade glioma, according to the…

Improvements needed to better integrate PCPs into cancer survivorship care

February 24, 2017
Several cancer survivorship care models are available to help integrate primary care providers into the long-term follow-up care of cancer survivors…

Many patients lack knowledge about advances in cancer diagnostics, treatment

February 22, 2017
A majority of patients with cancer and their caregivers lack sufficient knowledge about advances in diagnostic and treatment options, according to…

In the Journals Plus

Many nonelderly cancer survivors alter prescription drug use to save money

February 21, 2017
Nearly one-third of nonelderly Americans recently diagnosed with cancer change their prescription drug use for financial reasons, according to an…

Society leaders: 2017 likely to be time of ‘unprecedented’ advances in hematology, oncology

February 20, 2017
This calendar year could be a pivotal one for oncology and hematology research, drug approvals and clinical trial results. In 2016, several new…

BERG initiates trial of BPM 31510-IV for glioblastoma

February 16, 2017
BERG LLC has initiated a phase 1/phase 2 clinical trial to evaluate BPM 31510-IV as monotherapy for patients with glioblastoma multiforme. The…

FDA: More adolescents with cancer should be included in adult trials

February 13, 2017
Enrollment of adolescents in oncology trials remains significantly lower than that of children. Consequently, the FDA has urged the research…

In the Journals Plus

Use of metaphors may improve participation in clinical trials

February 11, 2017
The use of metaphors for explaining randomization could ease the difficulty in recruiting patients to participate in randomized clinical trials…

‘Explosive growth’ of interventional oncology prompts formation of new society

February 10, 2017
The board of directors for World Conference on Interventional Oncology, a nonprofit association that supports and promotes the field, has established…

Eight updates in cancer prevention

February 10, 2017
National Cancer Prevention Month, established by a U.S. Senate resolution and observed every February since 2004, is intended to draw attention to…

More Headlines »
Advertisement
Advertisement